BMO Capital Reconfirms Alder Biopharmaceuticals (NASDAQ:ALDR) As a “Buy”; They Now Have a PT Of $22.0

April 22, 2018 - By Peter Erickson

Alder Biopharmaceuticals (NASDAQ:ALDR) Rating Reaffirmed

Alder Biopharmaceuticals (NASDAQ:ALDR) just had their share rating of a ‘”Buy”‘ issued by research analysts at BMO Capital, who now has a $22.0 PT on the $932.87M market cap company or a 60.00 % upside potential. This key information was disclosed in a research report on Tuesday, 2 January.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Coverage

Among 4 analysts covering Alder BioPharmaceuticals (NASDAQ:ALDR), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alder BioPharmaceuticals has $26.0 highest and $20.0 lowest target. $24.50’s average target is 78.18% above currents $13.75 stock price. Alder BioPharmaceuticals had 8 analyst reports since October 27, 2017 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Thursday, February 8. Canaccord Genuity maintained it with “Buy” rating and $22.0 target in Friday, January 12 report. The stock has “Buy” rating by RBC Capital Markets on Monday, January 8. The rating was maintained by BMO Capital Markets with “Buy” on Tuesday, January 2. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) earned “Buy” rating by BMO Capital Markets on Monday, January 8. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, January 30. Needham maintained Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) rating on Wednesday, November 8. Needham has “Buy” rating and $26.0 target.

The stock decreased 3.17% or $0.45 during the last trading session, reaching $13.75. About 655,695 shares traded. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 46.26% since April 22, 2017 and is downtrending. It has underperformed by 57.81% the S&P500.

Analysts await Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) to report earnings on April, 26. They expect $-1.26 EPS, up 36.68 % or $0.73 from last year’s $-1.99 per share. After $-0.80 actual EPS reported by Alder Biopharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 57.50 % negative EPS growth.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $932.87 million. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: